Sana Biotechnology
biotechnology company
SANA Nasdaq
SEC CIK 1770121
Follow Sana Biotechnology
Weekly email: filings, results
Net income
$20.4M
+148.4% vs same quarter last year
EPS, diluted
$0.07
+143.8% vs same quarter last year
Operating cash flow
−$38.8M
−31.7% vs same quarter last year
Operating income
$18.5M
+142.5% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY25 | −$244.2M |
| FY24 | −$266.8M |
| FY23 | −$283.3M |
| FY22 | −$269.5M |
| FY21 | −$355.9M |
| FY20 | −$285.3M |
| FY19 | −$130.8M |
| FY18 | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$144.8M |
| FY24 | −$256.6M |
| FY23 | −$273.6M |
| FY22 | −$310.9M |
| FY21 | −$280.9M |
| FY20 | −$161.9M |
| FY19 | −$111.6M |
| FY18 | - |